Andere talen Abliva AB Deutsche Boerse AG

Aandelen

NTP

SE0002575340

Vertraagde tijd Deutsche Boerse AG Andere beurzen 09:46:25 17-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0128 ^EUR	+0,79%		+70,67%	+4,07%

30/05	Abliva beëindigt dosering in mid-fase onderzoek naar medicijn tegen mitochondriale ziekten	MT
30/05	Abliva AB (Publ) kondigt de voltooiing aan van 24 weken dosering in Wave 1 van de Falcon-studie van KL1333 bij primaire mitochondriale ziekte	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Amended number of shares and votes in Abliva AB (publ)	31/05
Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	30/05
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease	30/05
Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	30/05
Ablivas CEO to BioStock: "We remain on track for the interim analysis early in Q3"	29/05
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024	23/05
Abliva : Interim Report January - March 2024	23/05
Abliva AB Interim Report January – March 2024	23/05
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23/05
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024	13/05
Amended number of shares and votes in Abliva AB (publ)	30/04
Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue	25/04
Abliva AB Publishes 2023 Annual Report	24/04
Notice of Annual General Meeting of Abliva AB (publ)	22/04
Abliva publishes rights issue outcome	19/04
BioStock: Abliva's mission to become mitochondrial medicine powerhouse	08/04
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares	27/03
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)	26/03
BioStock: Abliva's CEO comments on the proposed capital raise	29/02
Abliva AB Year-End Report January – December 2023	23/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Abliva AB Deutsche Boerse AG

Aandelen

NTP

SE0002575340

Andere talen

Filters